Drug Discovery World

SEPTEMBER 25, 2023

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.

Genome 52

Genome Genomics Gene Editing Medicine 52

Roots Analysis

JUNE 1, 2022

Many diseases that can be treated using DNA cloning, such as leukemia and sickle cell anemia, involving the replacement of defected gene. The pandemic has specifically resulted in enhanced research and development activities in the field of biotechnology. DNA Cloning Reagent Providers – Current Market Landscape.

DNA 52

DNA Genetics Reagent Marketing 52

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing. Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more. The post New whitepaper: Take a deep dive into cell therapy appeared first on Drug Discovery World (DDW).

Reagent 52

Reagent Manufacturing Development Research 52

FDA Law Blog

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

Drug Discovery World

JANUARY 30, 2024

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing.

Reagent 52

Reagent Manufacturing Development Drugs 52

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Posted 17 May 2021 | By Joanne S. Eglovitch . Historical origins. .

Development 52

Development Gene Therapy Manufacturing Gene 52

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

DECEMBER 16, 2022

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Drawing on 25 years in clinical research, White will oversee Saama’s project delivery teams. Other pharma supplier hires.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

Roots Analysis

FEBRUARY 23, 2022

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. During our research, we came across more than 280 NGS library preparation kits, that are presently available in the market.

Genetics 52

Genetics DNA RNA Reagent 52

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

MAY 7, 2024

The goal of these approaches is to improve process economics by eliminating steps and the amount of reagents, water and buffer. DC: We’ve seen in the last decade or so a lot of research and interest in the use of single-use technologies.

Antibody 59

Antibody Production Manufacturing Engineer 59

Drug Discovery World

OCTOBER 12, 2022

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

JULY 18, 2023

Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields, providing a versatile tool for precise and efficient genome editing. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

FEBRUARY 27, 2023

The system features high-throughput fast dual detectors, enabling researchers to screen millions of samples with the increased accuracy, speed and sensitivity. This enables researchers to perform a wide range of assays for different applications within one instrument.

Drugs 52

Drugs Life Science Protein Scientist 52

Drug Discovery World

JUNE 14, 2023

In addition to the collection, processing and storing of adult blood projects, BCA is also involved in providing umbilical cord blood and other tissue products as critical components of cell therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. . Looking forward .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52